A detailed history of Vanguard Group Inc transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,297,249 shares of LRMR stock, worth $9.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,297,249
Previous 2,537,489 9.47%
Holding current value
$9.21 Million
Previous $18.4 Million 18.21%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$6.3 - $10.68 $1.51 Million - $2.57 Million
-240,240 Reduced 9.47%
2,297,249 $15 Million
Q2 2024

Aug 13, 2024

BUY
$6.33 - $9.89 $1.07 Million - $1.68 Million
169,788 Added 7.17%
2,537,489 $18.4 Million
Q1 2024

May 10, 2024

BUY
$4.2 - $13.28 $3.83 Million - $12.1 Million
912,458 Added 62.7%
2,367,701 $18 Million
Q4 2023

Feb 14, 2024

BUY
$2.35 - $4.71 $64,662 - $129,600
27,516 Added 1.93%
1,455,243 $6.62 Million
Q3 2023

Nov 14, 2023

BUY
$3.08 - $4.49 $111,268 - $162,205
36,126 Added 2.6%
1,427,727 $5.64 Million
Q2 2023

Aug 14, 2023

BUY
$3.13 - $5.27 $313,597 - $528,006
100,191 Added 7.76%
1,391,601 $4.36 Million
Q1 2023

May 15, 2023

BUY
$4.0 - $6.68 $819,984 - $1.37 Million
204,996 Added 18.87%
1,291,410 $5.85 Million
Q4 2022

Feb 10, 2023

BUY
$2.73 - $5.08 $359,415 - $668,802
131,654 Added 13.79%
1,086,414 $4.49 Million
Q3 2022

Nov 14, 2022

BUY
$1.53 - $3.64 $678,827 - $1.61 Million
443,678 Added 86.81%
954,760 $3.06 Million
Q1 2022

May 13, 2022

SELL
$3.65 - $10.84 $54,607 - $162,177
-14,961 Reduced 2.84%
511,082 $2.07 Million
Q4 2021

Feb 14, 2022

BUY
$8.86 - $13.47 $1.03 Million - $1.56 Million
115,727 Added 28.2%
526,043 $5.68 Million
Q3 2021

Nov 12, 2021

SELL
$9.61 - $15.11 $2.44 Million - $3.84 Million
-254,054 Reduced 38.24%
410,316 $4.73 Million
Q2 2021

Aug 13, 2021

BUY
$8.0 - $15.2 $5.31 Million - $10.1 Million
664,370 New
664,370 $6.53 Million

Others Institutions Holding LRMR

About Larimar Therapeutics, Inc.


  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $174M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.